ARTICLES BY MATTHEW PILLAR

• Debra Weiss, RN: Big Impact In Small, Non-Profit Bio

  3/8/2024

  The career of Debra Weiss, RN, MSN, and COO at the biopharma Gates Medical Research Institute (Gates MRI), offers a case study in creating success through service-oriented leadership.

• Legal And IP Protection For New Biotechs

  10/31/2023

  Want to ensure you've got your biotech legal, IP, and patent bases covered? Join Business of Biotech host Matt Pillar and BlueSphere Bio CEO and biotech legal expert Keir LoIacono on 11/13 for the live, interactive, and FREE digital event Legal And IP Protection For New Biotechs. 

• FDA Submission Automation: Coming To A Cloud Near You

  2/15/2023

  The FDA is laying the groundwork for standardized, cloud-based electronic submission standards via an initiative that leverages data automation and artificial intelligence. What will it mean to biopharma filers?

• Navigating A Clinical Hold

  9/7/2022

  FDA-ordered clinical holds are on the rise, and biologics IND are driving them. Immunome CEO Purnanand Sarma, Ph.D. shares his take on the role of the clinical hold, the biopharma’s appropriate response, and advice on obviating for the circumstance.

• Biologics Clinical Research: The Year’s Best

  4/16/2021

  Harry Selker, M.D. sits down with BioProcess Online for a candid discussion on the Clinical Research Forum’s work, its awards program that recognizes the year's best advances in clinical and translational research, and why that’s such an important structural element in the bridge between academia and industry. 

• The Compounded Risk Of Early-Stage Biopharma Licensing Deals

  6/25/2020

  For emerging biopharma firms, licensing options can equal a boon to the business when cash runways are short and financing options run thin. But, there’s a catch. Most licensed candidates fail. And, according to a new paper, rushed licensing deals on the heels of phase 3 clinical failures only compound the disappointment.